Acute Myeloid Leukemia Clinical Trial
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
This is a first-in-human, open-label, phase 1, sequential dose escalation study. AMG 673 will be evaluated as a short term intravenous (IV) infusion in adult subjects with relapsed/refractory AML. The study will be conducted at approximately 7 sites in the United States, Australia and Germany.
This is a first-in-human, open-label, phase 1, sequential dose escalation study. Emerfetamab will be evaluated as a short term intravenous (IV) infusion in adults with relapsed/refractory AML The study will consist of a dose escalation phase and a dose expansion phase. The study was terminated prior to the start of the expansion phase.
Subject has provided informed consent prior to initiation of any study-specific activities/procedures.
Subjects ≥ 18 years of age at the time of signing consent.
AML as defined by the World Health Organisation (WHO) Classification persisting or recurring following 1 or more treatment courses except promyelocytic leukemia (APML).
More than 5% myeloblasts in bone marrow.
Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
Known hypersensitivity to immunoglobulins.
Autologous hematopoietic stem cell transplantation (HSCT) within 6 weeks prior to start of AMG 673 treatment.
Allogeneic HSCT within 3 months prior to start of AMG 673 treatment.
Non-manageable graft versus host disease.
Known positive test for human immunodeficiency virus (HIV).
Males and females of reproductive potential who are unwilling to practice a highly effective method(s) of birth control while on study through 15 weeks after receiving the last dose of study drug. Acceptable methods of highly effective birth control include sexual abstinence (males, females); vasectomy; bilateral tubal ligation/occlusion; or a condom with spermicide (men) in combination with hormonal birth control or intrauterine device (IUD) (women). Males who are unwilling to abstain from sperm donation while on study through 5 half-lives after receiving the (last [multiple-dose studies]) dose of study drug.
Females who are lactating/breastfeeding or who plan to breastfeed while on study through 15 weeks after receiving the last dose of study drug.
Females with a positive pregnancy test
Females planning to become pregnant while on study through 15 weeks after receiving the last dose of study drug.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Birmingham Alabama, 35294, United States
Duarte California, 91010, United States
Houston Texas, 77030, United States
Seattle Washington, 98109, United States
Melbourne Victoria, 3004, Australia
Parkville Victoria, 3050, Australia
MÃ¼nchen , 81377, Germany
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.